Please assess the completion status of the following clinical trial:

Trial Title: Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with metastatic or advanced-stage malignant tumor. Patients may have received up to 2 prior lines of chemotherapy for their metastatic disease~* ECOG score of 0 or 1~* Predicted life expectancy of ≥ 3 months~* Adequate bone marrow, liver and renal function renal function~* Adequate cardiac function~* For women: Negative pregnancy test for females of child-bearing potential; must be surgically sterile, postmenopausal, or compliant with a contraceptive regimen during and for 3 months after the treatment period~* For men: Must be surgically sterile, or compliant with a contraceptive regimen during and for 3 months after the treatment period~* For Part 2 of the Study only, patients must have measurable disease by RECIST 1.1 and be in one of the the groups below. Patients in groups 1, 2, 4, 5 and 6 may not have been previously treated with BRAF and/or MEK inhibitors~  * Group 1: Patients with BRAF mutated cancer, except those with colorectal or non-small cell lung cancers~ * Group 2: Patients with BRAF mutated colorectal cancer~ * Group 3: Patients with BRAF mutated melanoma who have progressed on, or are refractory to BRAF and/or MEK inhibitors~ * Group 4: Patients with NRAS mutated melanoma~ * Group 5: Patients with MEK mutated cancer~ * Group 6: Patients with BRAF mutated non-small cell lung cancer~ * Group 7: Patients with ERK mutated cancer~Exclusion Criteria:~* Gastrointestinal condition which could impair absorption of study medication~* Uncontrolled or severe intercurrent medical condition~* Known uncontrolled brain metastases. Stable brain metastases either treated or being treated with a stable dose of steroids/anticonvulsants~* Any cancer-directed therapy (chemotherapy, radiotherapy, hormonal therapy, biologic or immunotherapy, etc.) within 28 days or 5 half-lives, whichever is shorter~* Major surgery within 4 weeks prior to first dose~* Any use of an investigational drug within 28 days or 5 half-lives (whichever is shorter) prior to the first dose of BVD-523.~* Pregnant or breast-feeding women~* Any evidence of serious active infections~* Any important medical illness or abnormal laboratory finding that would increase the risk of participating in this study~* A history or current evidence/risk of retinal vein occlusion or central serous retinopathy~* Concurrent therapy with any other investigational agent~* Concomitant malignancies or previous malignancies with less than 2 years disease-free interval at the time of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BVD-523 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).